Intrexon | XON - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agenus USD -221.22M 241.03M 2026-03
Alaunos Therapeutics USD 1.01M 175K 2026-03
Amgen USD 4.78B 1.12B 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 215M 8.23M 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Intrexon USD 61.56M 26.1M 2024-06
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Ligand Pharmaceuticals USD 34.35M 5.27M 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
MannKind USD 110.9M 8.74M 2026-03
Merck USD 18.17B 8.01B 2026-03
Novartis USD 9.29B 507M 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Thermo Fisher Scientific USD 9.09B 821M 2026-03
Veracyte USD 119.99M 3.99M 2026-03
Xencor USD 82.38M 513K 2026-03